Full-Time

Medical Science Liaison

India, Immunology & Inflammation

Beeline Medicines

Beeline Medicines

51-200 employees

Clinical-stage biotech developing precision autoimmune therapies

No salary listed

India

Remote

Field-based role covering India and other assigned Asia-Pacific countries; regular travel is required, potentially 50% or more.

PharmD, PhD, MD

Category
Biology & Biotech
Required Skills
FDA Regulations

Get referred to Beeline Medicines

See people who can refer or advise you

Requirements
  • An advanced degree is required: PharmD, PhD, or MD in a relevant life sciences, pharmacy, or biomedical field.
  • At least 3 years of MSL or related field-based medical affairs experience in the pharmaceutical or biotechnology industry is required for the MSL level.
  • At least 5 years of MSL or field-based medical affairs experience in the pharmaceutical or biotechnology industry is required for the Senior MSL level.
  • Professional fluency in English, written and verbal, is required.
  • Ability to safely and successfully operate a motor vehicle, maintain a valid driver's license, and meet company driving-record standards is required.
  • Ability to travel 50% or more as needed, including occasional overnight stays, is required.
  • Ability to work evenings and weekends as needed for physician or patient events, both in person and virtually, is required.
  • Depending on geography, ability to manage a multi-state territory with a diverse customer base is required.
  • For the MSL level, developing scientific and clinical knowledge of immunology and inflammation is required.
  • For the MSL level, ability to interpret and communicate clinical and scientific data, including study design, statistical concepts, and benefit-risk assessment, is required.
  • For the MSL level, working proficiency in customer relationship management platforms such as Veeva is required.
  • For the MSL level, working knowledge of medical-affairs compliance frameworks, including FDA and EMA regulations, PhRMA guidelines, and on-label and off-label scientific exchange, is required.
  • For the Senior MSL level, advanced scientific and clinical expertise in immunology and inflammation is required.
  • For the Senior MSL level, expert ability to interpret, contextualize, and communicate complex clinical and translational data, including study-design nuances, subgroup analyses, and evolving safety and efficacy profiles, is required.
  • For the Senior MSL level, established proficiency in Veeva CRM and medical-affairs field tools is required.
  • For the Senior MSL level, knowledge of PhRMA guidelines, FDA regulations, and investigator-initiated study management frameworks is required.
  • For the Senior MSL level, ability to synthesize and present complex field intelligence in structured, executive-ready internal communications is required.
  • For the Senior MSL level, experience facilitating and presenting in one-on-one KOL settings, investigator meetings, advisory-board participation, and large medical-congress environments is required.
Responsibilities
  • Contribute to development and refinement of medical strategy through field insights and healthcare professional, key medical expert, and investigator engagement.
  • Develop and execute territory plans aligned with organizational priorities and data milestones.
  • Develop and manage a defined territory of key medical expert and healthcare professional relationships within the Immunology & Inflammation therapeutic area.
  • Identify, map, and engage scientific thought leaders, clinical investigators, and academic centers relevant to the company pipeline under Medical Affairs leadership.
  • Develop Tier 1, Tier 2, and Tier 3 segmentation, strategic engagement plans, and longitudinal relationship ownership with healthcare professionals, key medical experts, and investigators.
  • Conduct peer-to-peer scientific exchange by sharing clinical and preclinical data, presenting pipeline updates, and discussing unmet medical needs in Immunology & Inflammation in a balanced, compliant, and scientifically rigorous manner.
  • Support clinical-trial awareness and site-identification efforts by engaging potential investigators and academic institutions in scientific discussions that may support site initiation and patient enrollment.
  • Serve as the key scientific-exchange resource and face of the sponsor for clinical-site investigators from site start-up through study closeout in collaboration with Clinical Operations.
  • Respond to unsolicited medical-information requests from healthcare professionals, key medical experts, and investigators in partnership with Medical Information and in accordance with applicable regulatory and compliance guidelines.
  • Serve as the field-based scientific resource for healthcare professional, key medical expert, and investigator interactions related to investigator-initiated studies.
  • Support the investigator-initiated study process by facilitating scientific discussions and coordinating with Medical Affairs leadership.
  • Support identification of evidence gaps and contribute to evidence-generation strategies.
  • Generate, synthesize, and translate insights into strategic recommendations, including key medical expert perspectives, competitive intelligence, clinical-practice trends, and unmet-need observations, for Medical Affairs, Clinical Development, and other cross-functional teams.
  • Represent the company at scientific conferences, medical congresses, and advisory-board meetings within the Immunology & Inflammation therapeutic area.
  • Lead and manage a strategically defined territory of senior key medical expert, clinical investigator, and academic-center relationships with full independence.
  • Develop and refine territory strategy based on evolving data milestones, key medical expert influence mapping, and clinical-development priorities.
  • Conduct sophisticated peer-to-peer scientific exchange with senior thought leaders, clinical investigators, and healthcare professionals on emerging clinical data, benefit-risk considerations, and evolving disease paradigms.
  • Serve as a senior field resource for clinical-trial support, including investigator identification, scientific site engagement, and enrollment-strategy discussions with Clinical Development and Clinical Operations.
  • Own and manage investigator-initiated study relationships within the territory, serve as the primary scientific contact for investigators, facilitate the review process, and maintain scientific engagement with funded sites.
  • Synthesize and present strategic key medical expert engagement insights and field intelligence to Medical Affairs leadership, Clinical Development, and strategy teams.
  • Contribute to development of MSL scientific-training materials, field tools, and disease-area resources.
  • Represent the company at major national and international scientific conferences, advisory boards, and key medical expert forums.
  • Contribute to advisory-board development and execution, including key medical expert identification, scientific input into agenda design, and synthesis of outcomes into strategic recommendations.
Desired Qualifications
  • Post-doctoral training, clinical fellowship, or residency in a relevant discipline.
  • Experience in immunology, inflammation, or a related therapeutic area for the MSL level.
  • Clinical-stage biotechnology experience.
  • Prior involvement in investigator-initiated study management or clinical-trial support activities.
  • Experience in immunology, inflammation, or a closely related therapeutic area for the Senior MSL level.
  • Experience with digital engagement platforms and virtual scientific exchange.
  • Experience leveraging artificial-intelligence-driven and omnichannel engagement strategies.
  • Ability to guide junior colleagues on compliance questions.

Beeline Medicines is a clinical-stage biotechnology company focused on precision therapies for autoimmune and inflammatory diseases, formed after in-licensing five programs from Bristol Myers Squibb with a $300 million Series A led by Bain Capital. Its lead programs include afimetoran, an oral lupus therapy that inhibits TLR7 and TLR8, lomedeucitinib, an allosteric TYK2 inhibitor, and two IND-stage biologics targeting IL-18 and IL-10 pathways. The drugs work by modulating specific immune signaling pathways to reduce inflammation, with afimetoran designed to address lupus drivers. The company differentiates itself by using in-licensed assets from a major pharma partner and combining them with an experienced leadership team to push multiple programs toward pivotal trials, starting with Phase 2 for afimetoran targeted for late 2026.

Company Size

51-200

Company Stage

Series A

Total Funding

$426.3M

Headquarters

Stamford, Connecticut

Founded

2025

Get referred to Beeline Medicines

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Beeline closed a $126.3 million extension on June 30, 2026, reaching $426.3 million.
  • FDA Fast Track for afimetoran in May 2025 accelerates regulatory interaction.
  • Management plans several clinical starts within 12 months, expanding catalysts beyond lupus.

What critics are saying

  • Afimetoran’s Phase 2 lupus readout in H2 2026 is the company’s make-or-break catalyst.
  • Failure versus Benlysta, Saphnelo, and competing lupus drugs kills the pivotal plan.
  • Five BMS-origin assets concentrate scientific risk; one bad readout can crush financing appetite.

What makes Beeline Medicines unique

  • BMS licensed five programs to Beeline in 2025, de-risking discovery.
  • Afimetoran targets TLR7/8, an upstream lupus mechanism unlike downstream cytokine biologics.
  • Saqib Islam and SpringWorks veterans bring repeatable biotech execution and exit experience.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Flexible Work Hours

Paid Vacation

Paid Holidays

Health Insurance

Company Equity

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

-8%

1 year growth

-8%

2 year growth

-8%
Beeline Medicines
Jun 30th, 2026
Terms of Use - Beeline Medicines

Terms of Use Agreement Effective: April 8, 2026 1. Acceptance of the Terms and Conditions. Beeline Medicines Corporation (herein referred to as “Beeline,” “we,” “us” or “our”) provides and makes available this web site (the “Web Site”). All use of the Web Site is subject to the terms and conditions contained in this Terms of […]

Fierce Biotech
Jun 29th, 2026
BMS-backed Beeline raises $126M series A extension for autoimmune programs

Beeline Medicines has raised $126.3 million in a Series A extension, just two and a half months after emerging from stealth with $300 million in funding and five autoimmune programmes from Bristol Myers Squibb. The biotech startup, backed by BMS, is developing treatments targeting autoimmune diseases. The additional funding comes as the company rapidly advances its pipeline following its December debut. Details about the extension round's investors and the company's specific plans for the new capital were not disclosed.

Yahoo Finance
Apr 15th, 2026
Beeline debuts with $300M and immune drugs licensed from Bristol Myers

Beeline Medicines emerged from stealth with $300 million in Series A funding from Bain Capital to develop precision therapies for immune diseases. The company's pipeline includes five experimental medicines licensed from Bristol Myers Squibb nearly a year ago. Beeline's lead asset is afimetoran, a daily oral treatment for systemic lupus erythematosus targeting immune system receptors. A Phase 2 study is expected to complete in the second half of this year, with a pivotal programme planned thereafter. The pipeline also includes candidates for atopic dermatitis, lupus and plaque psoriasis, plus two preclinical assets. Saqib Islam, former CEO of SpringWorks Therapeutics, leads the company. Bain Capital previously backed Cerevel Therapeutics, acquired by AbbVie for nearly $9 billion, and Aiolos Bio, purchased by GSK.

Dealroom.co
Apr 15th, 2026
Beeline Medicines company information, funding & investors

Beeline Medicines, precision therapies for autoimmune and inflammatory diseases. Here you'll find information about their funding, investors and team.

GlobeNewswire
Apr 15th, 2026
Beeline Medicines Debuts to Deliver Category-Leading Precision Therapies for People Living with Autoimmune and Inflammatory Diseases

– Advancing a broad portfolio designed to deliver multiple paradigm-shifting therapies for devastating and underserved immune-mediated diseases –  – Lead...